The National Institute for Health and Care Excellence (NICE) published advice in July 2016 in relation to ataluren (Translarna®) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older. At their meeting on 13 July 2016 AWMSG supported the adoption and implementation of this advice within NHS Wales. Welsh Government has subsequently agreed that the NICE HST advice for ataluren (Translarna®) should be implemented within NHS Wales. Refer to HST22 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for full guidance on NICE recommendations, including any specific restrictions on the use of the technology.